Pharmaceutical intermediates
Carfilzomib Intermediates
5 pharmaceutical intermediates for Carfilzomib. Indication: Multiple myeloma.
About Carfilzomib
- Originator
- Onyx Pharmaceuticals Inc
- Indication
- Multiple myeloma
- Approved Date
- 07/20/2012
Available intermediates
5 intermediates currently listed for Carfilzomib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| CarbaMic acid, N-[(1S)-3-Methyl-1-[[(2R)-2-Methyl-2-oxiranyl]carbonyl]butyl]-, 1,1-diMethylethyl ester | 247068-82-2 | / | / |
| 1-Pentanone, 2-aMino-4-Methyl-1-[(2R)-2-Methyloxiranyl]-, (2S)-, trifluoroacetate (9CI) | 247068-85-5 | / | / |
| (alphaS)-alpha-Aminobenzenebutanoyl-L-leucyl-L-phenylalanine methyl ester | 868539-98-4 | / | / |
| (alphaS)-alpha-Aminobenzenebutanoyl-L-leucyl-L-phenylalanine methyl ester mono(trifluoroacetate) | 868539-99-5 | / | / |
| (alphaS)-alpha-[[2-(4-Morpholinyl)acetyl]amino]benzenebutanoyl-L-leucyl-L-phenylalanine methyl ester | 1140908-89-9 | / | / |
Building toward Carfilzomib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →